This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss)처그-스트라우스 증후군 (Churg-Strauss증후군)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: M30.1 | Special Copayment Reduction: V134 (rare disease Special Copayment Reduction)
B. SynonymsPolyarteritis with lung involvement | Churg-Strauss syndrome
C. Adult onsetPossibility of first onset in adulthood: high — in almost all patients, adult-onset asthma precedes the vasculitic phase by several years, and it is most often diagnosed in middle-aged adults in their 30s–50s. Occurrence in children is extremely rare. It is common for diagnosis to be delayed by several years after asthma first develops in adulthood.
1. History1951: first description by Churg·Strauss (eosinophilic granuloma + vasculitis + asthma) → 2012: renamed EGPA by the CHCC.
2. CausesANCA (mainly MPO) positive in 40–60%; underlying asthma/allergy is essential. Th2 immune skewing, IL-5-driven eosinophil activation, hypothesis of an association with leukotriene antagonists.
3. GeneticsHLA-DRB4 association; clinical and genetic differences between the ANCA-positive (MPO) and ANCA-negative subtypes. Genetic variants in the IL-5 pathway.
4. General epidemiologyPrevalence 0.5–6.8 per 100,000; onset in the 30s–50s; similar in men and women. In patients with underlying asthma, 64 cases per million population per year.
5. PathophysiologyIL-5-driven eosinophil activation → tissue infiltration (heart, nerves, skin) + ANCA-mediated neutrophil activation → small-vessel necrotizing vasculitis + formation of eosinophilic granulomas.
6. SymptomsAsthma (essential) + eosinophilia + mononeuritis multiplex + skin purpura/nodules + heart (myocarditis, heart failure) + sinusitis. Three-phase clinical course.
7. SignsEosinophil count >1,500/μL (essential); ANCA (MPO) positive in 40–60%; migratory infiltrates on chest imaging; signs of myocarditis; asymmetric neurological deficits.
8. ScreeningRegular eosinophil counts in patients with severe adult-onset asthma; ANCA panel; cardiac MRI (early detection of cardiac involvement); nerve conduction studies.
9. DiagnosisACR 1990 criteria (4/6 items) + eosinophils >10% (or >1,500/μL) + asthma. Tissue biopsy (eosinophilic vasculitis + granuloma). ANCA, cardiac MRI.
10. TreatmentFirst-line: steroids (mild) or steroids + cyclophosphamide (severe). Second-line: mepolizumab (anti-IL-5). ANCA-associated vasculitis subtype: consider rituximab.
11. Prognosis5-year survival about 90% or more; cardiac involvement is the main cause of death; relapse in 50% or more. High steroid dependence, so be alert to long-term complications.
12. PreventionAvoid rapid steroid tapering when asthma is controlled; regular cardiac testing; mepolizumab maintenance in relapsing cases; prevention of immunosuppression complications.
13. References10 major international journals and guidelines

1. History

The history of Churg-Strauss syndrome begins in 1951 with a paper in which the American pathologists Jacob Churg and Lotte Strauss compiled and described unusual cases of systemic vasculitis occurring in patients with asthma. They analyzed 13 cases in which asthma, eosinophilia, extravascular granulomas and necrotizing vasculitis of small and medium-sized vessels appeared together, and proposed this disease as an independent clinical entity. At the time there was debate over whether it should be regarded as a type of polyarteritis nodosa or as a separate disease, but as the characteristic eosinophilic granuloma findings were recognized as a unique feature distinguishing it from other vasculitides, it gradually became established as an independent disease.

In 1984, Lanham et al. systematized the clinical course of this syndrome into three phases. Phase 1 is the allergic prodromal phase, in which allergic rhinitis and asthma develop over several years; phase 2 is the eosinophilic infiltration phase, in which eosinophilia in blood and tissues is prominent; and phase 3 is the vasculitic phase, in which systemic vasculitis appears. This three-phase clinical course model was used as the textbook description for decades thereafter.

In 1990, the American College of Rheumatology (ACR) presented classification criteria with 6 items, and as ANCA testing became widespread it was found that MPO-ANCA is positive in about 40–60% of patients, establishing the concept that ANCA-positive and ANCA-negative subtypes have clinically different characteristics. In 2012, the International Chapel Hill Consensus Conference (CHCC) revised the name to Eosinophilic Granulomatosis with Polyangiitis (EGPA), emphasizing eosinophilic infiltration and granuloma formation, the essential features of this disease. In Korea, the name Churg-Strauss syndrome is still in use, and the disease is managed under Special Copayment Reduction code V134.


2. Causes

The etiology of Churg-Strauss syndrome (EGPA) has not been fully elucidated, but it is understood as a complex interaction between allergic predisposition and autoimmune mechanisms. Almost all patients have a history of asthma and allergy, suggesting that Th2 immune skewing plays an important role in the pathogenesis of this disease.

Th2 immune skewing and IL-5-mediated eosinophil activation: An excessive Th2 response to environmental antigens (inhaled allergens, drugs, etc.) causes oversecretion of IL-4, IL-5 and IL-13. IL-5 promotes eosinophil production in the bone marrow, recruits blood eosinophils into tissues and prolongs eosinophil survival. Eosinophils that infiltrate tissues become activated and release eosinophil major basic protein (MBP), eosinophil cationic protein (ECP), eosinophil-derived neurotoxin (EDN), reactive oxygen species and others, causing tissue damage and vascular inflammation.

Role of ANCA: MPO-ANCA (perinuclear ANCA, p-ANCA) is positive in about 40–60% of patients, and PR3-ANCA is positive in a minority. ANCA-positive patients are reported to more commonly have small-vessel involvement such as glomerulonephritis and mononeuritis multiplex, whereas ANCA-negative patients more often have cardiac involvement, eosinophilic endocarditis and the like. ANCA is thought to activate neutrophils and monocytes, causing vascular endothelial cell damage.

Leukotriene antagonist (LTRA) association hypothesis: From the late 1990s, cases of EGPA developing after use of leukotriene receptor antagonists (LTRAs) such as zafirlukast and montelukast were reported, raising the possibility of drug induction. However, it is currently interpreted not that LTRAs directly cause EGPA, but that in underlying latent EGPA the vasculitic phase becomes manifest as steroid inhalers are reduced with the introduction of LTRAs.

Genetic predisposition: HLA-DRB4 positivity has been reported as a susceptibility factor for EGPA, and IL-5 receptor gene polymorphisms, IgG Fc receptor gene polymorphisms and others are also being studied. Familial occurrence is rare but has been reported.


3. Genetics

Genetic research on Churg-Strauss syndrome (EGPA) is still ongoing, and no single causative gene has been identified. The disease is understood as a complex immune disease arising from a complex interaction between genetic susceptibility factors and environmental factors.

HLA associations: Studies of European and Japanese patients have repeatedly reported HLA-DRB4 (*0101 and *0103 alleles) as a susceptibility factor for EGPA. HLA-DRB4 is involved in CD4+ T-cell activation and antigen presentation and plays a role in regulating Th2-skewed immune responses. In contrast, some studies have reported that HLA-DRB3 has a protective effect. It shows HLA associations distinct from those of other ANCA-associated vasculitides (HLA-DPB1*0401 in Wegener's granulomatosis, HLA-DQ in microscopic polyangiitis).

Genetic differences between ANCA-positive and ANCA-negative subtypes: The concept that ANCA-positive and ANCA-negative EGPA patients may represent genetically and clinically different subtypes is gaining increasing support. In ANCA-positive patients, glomerulonephritis, small-vessel involvement and more pronounced autoimmune features are observed, while in ANCA-negative patients cardiac involvement and eosinophilic tissue infiltration are prominent. Some researchers regard ANCA-positive EGPA as part of the spectrum of other ANCA-associated vasculitides and ANCA-negative EGPA as closer to the spectrum of eosinophilic disorders.

Genetic variants in the IL-5 pathway: Studies suggest that polymorphisms of the IL-5 and IL-5 receptor α (IL-5Rα, CD125) genes are associated with EGPA susceptibility and severity. Because the IL-5 signaling pathway is the target of mepolizumab (an anti-IL-5 monoclonal antibody) therapy, research on genetic variants in this pathway is also clinically significant for predicting treatment response. STAT3 and STAT6 gene polymorphisms and IL-33–ST2 axis variants are also being studied in both EGPA and allergic asthma.


4. General epidemiology

Churg-Strauss syndrome (EGPA) is a very rare vasculitis, with a reported prevalence of about 10.7–13 per million population and an annual incidence of about 0.5–6.8 per million. Among patients with asthma, an annual incidence of about 64 per million asthma population has been reported.

Sex and age distribution: The sex difference is less pronounced than in polyarteritis nodosa or Wegener's granulomatosis; it occurs almost equally in men and women, or slightly more often in women in some studies. Age at onset ranges from 20 to 70 years but is most common in the middle-aged in their 30s–50s. EGPA in children is extremely rare and may have a clinical picture different from that in adults.

Preceding conditions: Asthma precedes the disease in almost all patients (about 95% or more), and vasculitis appears on average 3–9 years after the onset of asthma. Allergic rhinitis, sinusitis and skin allergies commonly accompany it. The asthma is often adult-onset asthma, which tends to be more severe and more strongly steroid-dependent than ordinary atopic asthma.

Epidemiology in Korea: In Korea, the number of patients registered under code M30.1 (Churg-Strauss syndrome) is limited. According to data based on patients registered under Special Copayment Reduction V134, the number of registered patients in Korea is understood to be fewer than several hundred, but the actual prevalent population may be larger because of the complexity of diagnosis. In Korea, where the prevalence of asthma is high, a system of collaboration between asthma specialists and rheumatology and neurology specialists is important for early identification of EGPA.

Worldwide, the treatment landscape has recently been changing with the introduction of mepolizumab (an anti-IL-5 monoclonal antibody), and reductions in EGPA relapse rates and steroid-sparing effects have been reported. Accordingly, as awareness of EGPA among medical staff increases, the number of new diagnoses is trending upward.


5. Pathophysiology

The pathophysiology of Churg-Strauss syndrome (EGPA) is understood as a dual mechanism in which eosinophil-mediated tissue damage and ANCA-mediated vasculitis act in combination.

Eosinophil activation and tissue infiltration: IL-5 oversecreted due to Th2 immune skewing amplifies eosinophil production in the bone marrow, sharply raises the peripheral blood eosinophil count (often >1,500/μL, sometimes >10,000/μL) and promotes eosinophil infiltration into tissues. When eosinophils that have infiltrated tissues are activated, they release eosinophil major basic protein (MBP), eosinophil cationic protein (ECP), eosinophil-derived neurotoxin (EDN) and reactive oxygen species, directly damaging the myocardium, nerve myelin sheaths and vessel walls. In particular, cardiac involvement results from eosinophilic endocardial infiltration and cardiomyocyte toxicity and progresses through a mechanism similar to endomyocardial fibrosis (Löffler endomyocardial fibrosis).

ANCA-mediated neutrophil activation: In MPO-ANCA-positive patients, the antibodies bind to MPO on the neutrophil surface and hyperactivate neutrophils. Activated neutrophils directly damage small-vessel endothelial cells through degranulation, generation of reactive oxygen species and release of NETs. This mechanism is shared with microscopic polyangiitis and Wegener's granulomatosis and explains why typical small-vessel lesions such as glomerulonephritis and mononeuritis multiplex appear in the ANCA-positive subtype of EGPA.

Formation of eosinophilic granulomas: Around blood vessels, extravascular granulomas composed of eosinophils, multinucleated giant cells and histiocytes form. These granulomatous lesions are the pathological hallmark of classic Churg-Strauss syndrome and consist of irregularly arranged cells around eosinophilic necrotizing lesions. Granuloma formation is thought to be induced by the interaction of histiocytes with Th1 cells secreting IL-12, IL-18 and INF-γ.

Bronchial and pulmonary involvement: Asthma is characterized by chronic eosinophilic infiltration of the bronchial mucosa, mucus hypersecretion and airway hyperresponsiveness, and in EGPA asthma is both a preceding stage and a persistent feature. Eosinophilic pneumonia results from eosinophilic infiltration of the alveoli and interstitium and appears on chest imaging as migratory pulmonary infiltrates.


6. Symptoms

The clinical picture of Churg-Strauss syndrome (EGPA) often follows the classic three-phase course proposed by Lanham, but the three phases do not necessarily appear sequentially.

Phase 1: allergic/prodromal phase: Asthma and allergic rhinitis are the main symptoms and can persist for years to decades. Asthma in this phase often arises as adult-onset disease and is more severe and more strongly steroid-dependent than ordinary asthma. Chronic sinusitis with nasal polyps is common. Patients are often misdiagnosed with simple asthma or allergic disease for years.

Phase 2: eosinophilic phase: The peripheral blood eosinophil count rises sharply (absolute count >1,500/μL, 10% or more of total white blood cells) and eosinophilic tissue infiltration appears. Migratory pulmonary infiltrates (eosinophilic pneumonia), abdominal pain and diarrhea due to gastrointestinal eosinophilic infiltration, and myocarditis due to cardiac eosinophilic infiltration mainly appear in this phase.

Phase 3: vasculitic phase: The phase in which systemic vasculitis appears, with systemic symptoms such as fever, weight loss and generalized fatigue together with vasculitic findings in the nervous system, skin, kidneys and elsewhere. Peripheral nerve involvement (mononeuritis multiplex) occurs in about 75%, typically as foot drop, wrist drop and burning pain in the limbs.

Cardiac involvement: In EGPA, cardiac involvement is the most important and life-threatening complication. Eosinophilic myocarditis, cardiomyopathy, pericarditis, endocarditis and heart failure can develop. Cardiac involvement is the main cause of death despite treatment, and early detection through cardiac MRI and myocardial enzyme tests is important.

Other symptoms: Skin purpura, subcutaneous nodules and ulcers; renal involvement (glomerulonephritis — in ANCA-positive patients); epistaxis, nasal polyps; arthralgia; gastrointestinal involvement (abdominal pain, bloody stools); and ocular symptoms (uveitis, conjunctivitis) may appear.


7. Signs

The physical signs and test findings for the diagnosis of Churg-Strauss syndrome (EGPA) are diverse, and the prominent findings differ depending on the phase.

Blood test findings: A peripheral blood absolute eosinophil count >1,500/μL is an essential feature of EGPA, and during active vasculitis it often rises to 10,000/μL or more. Elevated total IgE (reflecting allergic predisposition), elevated ESR and CRP, and leukocytosis are observed. MPO-ANCA (p-ANCA) positivity occurs in about 40–60%, and PR3-ANCA is positive in a minority. With cardiac involvement, elevated troponin I/T and BNP/NT-proBNP are observed.

Neurological signs: Asymmetric peripheral nerve deficits due to mononeuritis multiplex. Foot drop (peroneal nerve), wrist drop (radial nerve), paresthesia, burning pain. An asymmetric axonal damage pattern on nerve conduction studies.

Chest imaging findings: Chest X-ray and CT show migratory pulmonary infiltrates (transient, migratory pulmonary infiltrates), bronchial wall thickening, ground-glass opacities and pulmonary nodules. Pleural effusion can also occur. Lung lesions in EGPA are usually transient and respond well to steroids, distinguishing them from tuberculosis or infectious pneumonia.

Cardiac signs: Increased heart rate, heart murmur (valvular abnormality), signs of heart failure (jugular venous distension, pulmonary crackles, edema). Cardiac MRI is a key test for early detection of myocardial eosinophilic infiltration and fibrosis.

Skin signs: Purpura of the lower limbs, subcutaneous nodules (extravascular granuloma), livedo reticularis, skin ulcers.

1990 ACR classification criteria: Churg-Strauss syndrome is classified when 4 or more of the following 6 items are met (sensitivity 85%, specificity 99.7%). ① asthma, ② eosinophilia >10%, ③ mononeuropathy or polyneuropathy, ④ non-fixed pulmonary infiltrates, ⑤ paranasal sinus abnormality, ⑥ extravascular eosinophil infiltration.


8. Screening

There is no general population-wide screening test for Churg-Strauss syndrome (EGPA). However, targeted screening for early diagnosis in high-risk groups is clinically very important.

Screening in patients with asthma: In patients with adult-onset asthma, especially steroid-dependent severe asthma, EGPA should be suspected and eosinophil counts and a vasculitis panel performed in the following situations: when asthma control is poor and accompanied by eosinophilia; when sudden symptoms of mononeuritis multiplex appear in an asthma patient; when unexplained fever, weight loss or skin purpura develops in an asthma patient; when there is a pattern in which systemic symptoms worsen together with asthma exacerbation each time steroids are tapered.

Initial screening tests: Peripheral blood absolute eosinophil count (normal 100–500/μL; >1,500/μL in EGPA); MPO-ANCA, PR3-ANCA; total IgE, allergen-specific IgE; ESR, CRP; urinalysis (differentiation of glomerulonephritis); serum creatinine; troponin I/T, BNP/NT-proBNP (screening for cardiac involvement); chest X-ray or CT.

Cardiac screening tests: Because cardiac involvement is the main cause of death in EGPA, early screening with ECG, echocardiography and, if needed, cardiac MRI is recommended at diagnosis and during follow-up. Elevated cardiac troponin is an early indicator of myocarditis.

Neurological screening: When there are symptoms of neuropathy, nerve conduction studies (NCS) and electromyography (EMG) are used to determine the distribution and severity of mononeuritis multiplex.


9. Diagnosis

The diagnosis of Churg-Strauss syndrome (EGPA) is not confirmed by any single test and is made by comprehensive assessment of clinical symptoms, blood tests, imaging findings and histopathological findings.

1990 ACR classification criteria: Classified when 4 or more of 6 items (① asthma, ② eosinophils >10%, ③ mononeuropathy or polyneuropathy, ④ non-fixed pulmonary infiltrates, ⑤ paranasal sinus abnormality, ⑥ extravascular eosinophil infiltration) are met, with sensitivity 85% and specificity 99.7%. However, asthma and eosinophilia alone are not sufficient; evidence of vasculitis is essential.

Tissue examination (biopsy): Biopsy of skin purpura, gastrocnemius muscle, lung, myocardium, nasal mucosa and so on is used to confirm three pathological findings: ① necrotizing vasculitis of small and medium-sized vessels, ② eosinophilic infiltration of tissue, ③ extravascular eosinophilic granulomas. The presence of all three is diagnostic, but individual findings alone also support the diagnosis in the clinical context. Combined gastrocnemius muscle–saphenous nerve biopsy is useful for confirming vasculitis of the arteries supplying the nerves when mononeuritis multiplex is present.

Blood tests: absolute eosinophil count >1,500/μL, elevated total IgE, MPO-ANCA positivity (about 40~60%), and elevated ESR·CRP are typical. A negative ANCA does not exclude EGPA.

Chest imaging: on CT, migratory pulmonary infiltrates, peribronchial thickening, ground-glass opacities, pulmonary nodules, pleural effusion. Lung lesions are characteristically transient and migratory.

Cardiac MRI: the most sensitive test for early detection of eosinophilic myocardial infiltration and myocardial fibrosis. Subendocardial or intramyocardial enhancement on late gadolinium enhancement (LGE) cardiac MRI is a characteristic finding of cardiac involvement in EGPA.

Differential diagnosis: must be differentiated from hypereosinophilic syndrome (HES), allergic bronchopulmonary aspergillosis (ABPA), eosinophilic pneumonia, other vasculitides (polyarteritis nodosa, microscopic polyangiitis), parasitic infection, and others.


10. Treatment

Treatment of Churg-Strauss syndrome (EGPA) depends on severity and the presence of organ involvement. Treatment intensity is determined on the basis of the Five-Factor Score (FFS).

First-line treatment — glucocorticoids: in mild patients with an FFS of 0 (no major organ involvement), remission can be induced with oral prednisolone (1 mg/kg/day, maximum 80 mg/day). After a clinical response is achieved, the dose is tapered gradually over several months. Most EGPA patients can achieve remission with steroids alone, but relapse is common during steroid tapering.

First-line treatment — steroids + cyclophosphamide: in severe patients with FFS ≥ 1 or major organ involvement (heart, kidney, central nervous system), combination of steroids with cyclophosphamide (CYC) is recommended. After remission induction with intravenous pulse CYC (15 mg/kg every 2~3 weeks, 6 doses) or oral CYC (2 mg/kg/day), therapy is switched to azathioprine or methotrexate. More aggressive immunosuppression is needed when myocarditis is present.

Mepolizumab (anti-IL-5 monoclonal antibody): a biologic approved by the FDA in 2017 and the EMA in 2018 for the treatment of relapsing·refractory EGPA. It binds IL-5 and suppresses eosinophil production and survival. In the MIRRA trial, it showed significant effects in reducing steroid dose and prolonging relapse-free periods. It is also effective in controlling asthma·eosinophilia. Dose: 300 mg subcutaneously every 4 weeks. In Korea, coverage criteria for relapsing EGPA are also under review.

Rituximab (anti-CD20 monoclonal antibody): may be used in ANCA-positive EGPA patients as an alternative to cyclophosphamide or for refractory vasculitis. Evidence from other ANCA-associated vasculitides (Wegener's granulomatosis, microscopic polyangiitis) is considered applicable to the ANCA-positive subtype of EGPA.

Management of cardiac involvement: once eosinophilic myocarditis is diagnosed, high-dose steroid and immunosuppressant therapy is started immediately. Standard heart failure therapy (diuretics, ACE inhibitors/ARBs, beta-blockers) is given concurrently for heart failure and arrhythmias. Anticoagulation is considered for endocardial thrombus.


11. Prognosis

The prognosis of Churg-Strauss syndrome (EGPA) is relatively favorable compared with polyarteritis nodosa or Wegener's granulomatosis, with a reported 5-year survival rate of about 90% or higher. However, the relapse rate is high (over 50%) and steroid dependence is strong, so complications of long-term treatment are an important problem.

Main causes of death: cardiac involvement (eosinophilic myocarditis, heart failure) is the most common cause of death in EGPA, reported to account for about 50% or more of deaths. Minimizing damage to cardiac function through early diagnosis and aggressive treatment is important for improving prognosis. Renal failure, intestinal ischemia, and cerebrovascular involvement can also be causes of death.

FFS and prognosis: 5-year mortality in patients with a Five-Factor Score (FFS) ≥ 2 is markedly higher than in patients with an FFS of 0. This is why cardiac involvement is included as a 1-point FFS item.

Relapse and steroid dependence: EGPA has a very high relapse rate; even when remission is achieved with aggressive treatment, relapse is reported in about 50~75%. Recurrence of asthma·eosinophilia is particularly common during steroid tapering, and many patients must remain on low-dose steroids long term. Adverse effects of long-term steroid use (osteoporosis, diabetes, cataracts, Cushing's syndrome, infection) are an important cause of morbidity.

Peripheral nerve sequelae: mononeuritis multiplex improves after treatment, but complete recovery takes months~years, and in some patients neuropathic sequelae (paresthesia, chronic neuropathic pain) persist.

Prognostic benefit of mepolizumab: since the introduction of mepolizumab, steroid dose reduction has become possible and relapse intervals have lengthened, with a trend toward improved long-term prognosis. The reduction in cumulative steroid dose is also expected to lower the risk of long-term complications.


12. Prevention

There is no direct primary prevention for Churg-Strauss syndrome (EGPA). Currently available prevention focuses mainly on preventing relapse and long-term complications.

Caution during steroid tapering: in EGPA patients, tapering steroids too rapidly can cause asthma exacerbation and eosinophilia, and vasculitis may relapse. Tapering should be gradual while monitoring clinical symptoms, peripheral blood eosinophil count, and ESR/CRP. Because the first symptoms of EGPA may become manifest with use of leukotriene receptor antagonists (LTRAs), they should be used cautiously in patients with possible underlying vasculitis.

Regular cardiac evaluation: in all EGPA patients, ECG, echocardiography, troponin, and BNP are performed at diagnosis, and cardiac function is monitored regularly during treatment. Cardiac MRI is considered at diagnosis and for annual follow-up. Early detection of cardiac involvement translates directly into improved prognosis.

Relapse prevention — mepolizumab maintenance: in patients with high steroid dependence or repeated relapses, long-term maintenance therapy with mepolizumab (anti-IL-5) provides relapse prevention and steroid-sparing effects. Azathioprine or methotrexate is also used to maintain remission.

Prevention of immunosuppression complications: osteoporosis prevention (calcium, vitamin D, bisphosphonates), prevention of opportunistic infection (PCP prophylaxis, influenza·pneumococcal vaccines), blood glucose monitoring, and eye examinations (cataract·glaucoma) are essential in patients on long-term steroid therapy.

Asthma management: adequate control of underlying asthma is part of EGPA management. Asthma should be optimally controlled with a combination of inhaled steroids and bronchodilators, and the need to increase systemic steroids during asthma exacerbations should be recognized.

Patient education: patients are taught to notify their care team immediately if symptoms suggesting vasculitis relapse or cardiac involvement develop, such as new neuropathic symptoms (foot drop, hand weakness, burning pain in the limbs), chest pain, worsening dyspnea, or palpitations.


13. References

  1. Churg J, Strauss L. Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. Am J Pathol. 1951;27(2):277-301. PMID: 14819261.

  2. Masi AT, Hunder GG, Lie JT, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome. Arthritis Rheum. 1990;33(8):1094-1100. PMID: 2202310.

  3. Wechsler ME, Akuthota P, Jayne D, et al. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med. 2017;376(20):1921-1932. DOI: 10.1056/NEJMoa1702079. PMID: 28514601.

  4. Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1-11. DOI: 10.1002/art.37715.

  5. Guillevin L, Pagnoux C, Seror R, et al. The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides. Medicine (Baltimore). 2011;90(1):19-27. PMID: 21200183.

  6. Groh M, Pagnoux C, Baldini C, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) versus hypereosinophilic syndrome: 62 patients. Medicine (Baltimore). 2015;94(10):e651. DOI: 10.1097/MD.0000000000000651.

  7. Cottin V, Bel E, Bottero P, et al. Revisiting the systemic vasculitis in eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Autoimmun Rev. 2017;16(1):1-9. DOI: 10.1016/j.autrev.2016.09.018.

  8. Sablé-Fourtassou R, Cohen P, Mahr A, et al. Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med. 2005;143(9):632-638. PMID: 16263885.

  9. Vaglio A, Moosig F, Zwerina J. Churg-Strauss syndrome: update on pathophysiology and treatment. Curr Opin Rheumatol. 2012;24(1):24-30. DOI: 10.1097/BOR.0b013e32834daf1e.

  10. Guillevin L, Cohen P, Gayraud M, Lhote F, Jarrousse B, Casassus P. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore). 1999;78(1):26-37. PMID: 9990350.